402 related articles for article (PubMed ID: 30320896)
1. Lipidic prodrug approach for improved oral drug delivery and therapy.
Markovic M; Ben-Shabat S; Keinan S; Aponick A; Zimmermann EM; Dahan A
Med Res Rev; 2019 Mar; 39(2):579-607. PubMed ID: 30320896
[TBL] [Abstract][Full Text] [Related]
2. The prospects of lipidic prodrugs: an old approach with an emerging future.
Dahan A; Markovic M; Aponick A; Zimmermann EM; Ben-Shabat S
Future Med Chem; 2019 Oct; 11(19):2563-2571. PubMed ID: 31633401
[TBL] [Abstract][Full Text] [Related]
3. Prospects and Challenges of Phospholipid-Based Prodrugs.
Markovic M; Ben-Shabat S; Keinan S; Aponick A; Zimmermann EM; Dahan A
Pharmaceutics; 2018 Nov; 10(4):. PubMed ID: 30388756
[TBL] [Abstract][Full Text] [Related]
4. Rationale and applications of lipids as prodrug carriers.
Lambert DM
Eur J Pharm Sci; 2000 Oct; 11 Suppl 2():S15-27. PubMed ID: 11033424
[TBL] [Abstract][Full Text] [Related]
5. Molecular Modeling-Guided Design of Phospholipid-Based Prodrugs.
Markovic M; Ben-Shabat S; Keinan S; Aponick A; Zimmermann EM; Dahan A
Int J Mol Sci; 2019 May; 20(9):. PubMed ID: 31060339
[TBL] [Abstract][Full Text] [Related]
6. Smart design approaches for orally administered lipophilic prodrugs to promote lymphatic transport.
Elz AS; Trevaskis NL; Porter CJH; Bowen JM; Prestidge CA
J Control Release; 2022 Jan; 341():676-701. PubMed ID: 34896450
[TBL] [Abstract][Full Text] [Related]
7. Glyceride-Mimetic Prodrugs Incorporating Self-Immolative Spacers Promote Lymphatic Transport, Avoid First-Pass Metabolism, and Enhance Oral Bioavailability.
Hu L; Quach T; Han S; Lim SF; Yadav P; Senyschyn D; Trevaskis NL; Simpson JS; Porter CJ
Angew Chem Int Ed Engl; 2016 Oct; 55(44):13700-13705. PubMed ID: 27482655
[TBL] [Abstract][Full Text] [Related]
8. Phospholipid-drug conjugates as a novel oral drug targeting approach for the treatment of inflammatory bowel disease.
Dahan A; Markovic M; Epstein S; Cohen N; Zimmermann EM; Aponick A; Ben-Shabat S
Eur J Pharm Sci; 2017 Oct; 108():78-85. PubMed ID: 28627471
[TBL] [Abstract][Full Text] [Related]
9. Triglyceride-mimetic prodrugs of scutellarin enhance oral bioavailability by promoting intestinal lymphatic transport and avoiding first-pass metabolism.
Wang X; Zhang C; Han N; Luo J; Zhang S; Wang C; Jia Z; Du S
Drug Deliv; 2021 Dec; 28(1):1664-1672. PubMed ID: 34338567
[TBL] [Abstract][Full Text] [Related]
10. Targeted delivery of a model immunomodulator to the lymphatic system: comparison of alkyl ester versus triglyceride mimetic lipid prodrug strategies.
Han S; Quach T; Hu L; Wahab A; Charman WN; Stella VJ; Trevaskis NL; Simpson JS; Porter CJ
J Control Release; 2014 Mar; 177():1-10. PubMed ID: 24398334
[TBL] [Abstract][Full Text] [Related]
11. Lipids and Lipid-Processing Pathways in Drug Delivery and Therapeutics.
Markovic M; Ben-Shabat S; Aponick A; Zimmermann EM; Dahan A
Int J Mol Sci; 2020 May; 21(9):. PubMed ID: 32375338
[TBL] [Abstract][Full Text] [Related]
12. Advances in the use of prodrugs for drug delivery to the eye.
Taskar P; Tatke A; Majumdar S
Expert Opin Drug Deliv; 2017 Jan; 14(1):49-63. PubMed ID: 27441817
[TBL] [Abstract][Full Text] [Related]
13. Lipid-based drug carriers for prodrugs to enhance drug delivery.
Zaro JL
AAPS J; 2015 Jan; 17(1):83-92. PubMed ID: 25269430
[TBL] [Abstract][Full Text] [Related]
14. Long chain triglyceride-lipid formulation promotes the oral absorption of the lipidic prodrugs through coincident intestinal behaviors.
Tian CT; Guo JJ; Miao YF; Wang HL; Ye Q; Guo CL; Zhang MY; He ZG; Sun J
Eur J Pharm Biopharm; 2022 Jul; 176():122-132. PubMed ID: 35643367
[TBL] [Abstract][Full Text] [Related]
15. Rationalizing the selection of oral lipid based drug delivery systems by an in vitro dynamic lipolysis model for improved oral bioavailability of poorly water soluble drugs.
Dahan A; Hoffman A
J Control Release; 2008 Jul; 129(1):1-10. PubMed ID: 18499294
[TBL] [Abstract][Full Text] [Related]
16. Solid lipid matrix mediated nanoarchitectonics for improved oral bioavailability of drugs.
Banerjee S; Pillai J
Expert Opin Drug Metab Toxicol; 2019 Jun; 15(6):499-515. PubMed ID: 31104522
[No Abstract] [Full Text] [Related]
17. Lipid-Drug Conjugate for Enhancing Drug Delivery.
Irby D; Du C; Li F
Mol Pharm; 2017 May; 14(5):1325-1338. PubMed ID: 28080053
[TBL] [Abstract][Full Text] [Related]
18. Current prodrug design for drug discovery.
Hsieh PW; Hung CF; Fang JY
Curr Pharm Des; 2009; 15(19):2236-50. PubMed ID: 19601825
[TBL] [Abstract][Full Text] [Related]
19. Amorphous Solid Dispersions or Prodrugs: Complementary Strategies to Increase Drug Absorption.
Rumondor ACF; Dhareshwar SS; Kesisoglou F
J Pharm Sci; 2016 Sep; 105(9):2498-2508. PubMed ID: 26886316
[TBL] [Abstract][Full Text] [Related]
20. Targeted lipid based drug conjugates: a novel strategy for drug delivery.
Vadlapudi AD; Vadlapatla RK; Kwatra D; Earla R; Samanta SK; Pal D; Mitra AK
Int J Pharm; 2012 Sep; 434(1-2):315-24. PubMed ID: 22692074
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
